【瞩目】石药集团入局$100亿明星药

米内网2025-12-25

精彩内容日前，石药集团发布公告，集团开发的达雷妥尤单抗注射液在中国获临床试验批准，用于治疗多发性骨髓瘤成年患者。米内网数据显示，达雷妥尤单抗2024年在全球销售额超过100亿美元，在中国公立医疗机构终端销售额超过12亿元。集团开发的达雷妥尤单抗注射液是一种靶向ADP-核糖基环化（CD38）的重组全人源IgG1单克隆抗体，为原研药（商品名：兆珂）的生物类似药，该产品是按照治疗用生物制品新药3.3类...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594259136?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-25 16:45","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2594259136","market":"hk","top_or_hot":-1,"title":"【瞩目】石药集团入局$100亿明星药","media":"米内网","content":"<div>\n<p>精彩内容日前，石药集团发布公告，集团开发的达雷妥尤单抗注射液在中国获临床试验批准，用于治疗多发性骨髓瘤成年患者。米内网数据显示，达雷妥尤单抗2024年在全球销售额超过100亿美元，在中国公立医疗机构终端销售额超过12亿元。集团开发的达雷妥尤单抗注射液是一种靶向ADP-核糖基环化（CD38）的重组全人源IgG1单克隆抗体，为原研药（商品名：兆珂）的生物类似药，该产品是按照治疗用生物制品新药3.3类...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172647a4770164&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【瞩目】石药集团入局$100亿明星药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【瞩目】石药集团入局$100亿明星药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 16:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172647a4770164&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容日前，石药集团发布公告，集团开发的达雷妥尤单抗注射液在中国获临床试验批准，用于治疗多发性骨髓瘤成年患者。米内网数据显示，达雷妥尤单抗2024年在全球销售额超过100亿美元，在中国公立医疗机构终端销售额超过12亿元。集团开发的达雷妥尤单抗注射液是一种靶向ADP-核糖基环化（CD38）的重组全人源IgG1单克隆抗体，为原研药（商品名：兆珂）的生物类似药，该产品是按照治疗用生物制品新药3.3类...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172647a4770164&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0072913022.USD","symbol_name":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172647a4770164&s=b","article_id":"2594259136","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172647a4770164&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594259136","pubTimestamp":1766652317,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容日前，石药集团发布公告，集团开发的达雷妥尤单抗注射液在中国获临床试验批准，用于治疗多发性骨髓瘤成年患者。石药集团表示，集团的达雷妥尤单抗注射液研发遵循生物类似药相关研究指导原则，药学及非临床研究结果显示，该产品与原研药在质量、安全性和有效性方面高度相似，支持开展后续临床研究。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1191":"制药","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1515":"抗疫概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","01093":"石药集团","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC"},"translate_title":"[Attention] CSPC enters the $10 billion star drug market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5},"content_text":"精彩内容日前，石药集团发布公告，集团开发的达雷妥尤单抗注射液在中国获临床试验批准，用于治疗多发性骨髓瘤成年患者。米内网数据显示，达雷妥尤单抗2024年在全球销售额超过100亿美元，在中国公立医疗机构终端销售额超过12亿元。集团开发的达雷妥尤单抗注射液是一种靶向ADP-核糖基环化（CD38）的重组全人源IgG1单克隆抗体，为原研药（商品名：兆珂）的生物类似药，该产品是按照治疗用生物制品新药3.3类申报，适用于治疗多发性骨髓瘤成年患者。近年中国公立医疗机构终端达雷妥尤单抗销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局达雷妥尤单抗在近年销售规模快速增长，2024年在全球销售额超过100亿美元，在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额超过12亿元。米内网数据显示，达雷妥尤单抗注射液仅有强生拥有生产批文，暂无国内药企报产在审，杭州九源基因、正大天晴南京顺欣制药、石药集团巨石生物制药3家国内药企获批临床。石药集团表示，集团的达雷妥尤单抗注射液研发遵循生物类似药相关研究指导原则，药学及非临床研究结果显示，该产品与原研药在质量、安全性和有效性方面高度相似，支持开展后续临床研究。12月19日，石药集团发布公告，集团自主研发的化药1类创新药SYH2085片在中国获临床试验批准，该产品是一款可抑制流感病毒的RNA聚合酶酸性蛋白（PA）核酸内切酶活性的新型口服小分子候选药物，此次获批的临床适应症为用于治疗成人及12岁以上青少年单纯性甲型和乙型流感。12月18日，石药集团附属公司石药集团巨石生物制药开发的司库奇尤单抗注射液在用于治疗中度至重度斑块状银屑病的等效性III期临床试验中获得顶线分析数据，该产品是集团开发的全人源IgG1单克隆抗体药物，为司库奇尤单抗注射液（商品名：可善挺）的生物类似药。资料来源：米内网数据库、公司公告等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594259136","isCrawlerRequest":true}